Compare Ginkgo Bioworks Holdings Inc (DNA) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Oxford Lane Capital Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.33 (market cap $505.73M), while Oxford Lane Capital Corp trades at $9.47 (market cap $909.61M). The key difference: Oxford Lane Capital Corp is the larger of the two by market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | OXLC | |
|---|---|---|
Market Cap | $505.73M | $909.61M |
Sector | Health | Financials |
52-Week High | $16.14 | $18.75 |
52-Week Low | $5.48 | $8.15 |
Enterprise Value | $607.68M | — |
Dividend Yield | — | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
OXLC trades at $9.43, up 1.73% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 but high P/S of 92.8, with recent earnings misses and a volatile net income margin of 100.85% in 2026. Dividends of $0.20 monthly are ongoing, while news highlights NAV discounts and sustainability concerns.
Outlook is cautious due to earnings volatility and high yield risks; opportunities include deep NAV discounts, but risks involve unsustainable distributions and negative ROE/ROA. Analyst consensus is split, with 50% buy ratings reflecting divided sentiment on recovery potential versus financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
